In the randomized phase 3 RATIFY trail, standard induction therapy (daunorubicin and cytarabine (DNR/AraC), followed by consolidation with high-dose cytarabine) in combination with midostaurin showed longer OS and event-free intervals than chemotherapy alone in patients newly diagnosed with FLT3-mutated AML [113]. This evidence concerns the gene FLT3 and acute myeloid leukemia.